Study Title

Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate

Study Details

Description:

The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer

Sponsor:

Memorial Sloan Kettering Cancer Center

Contacts:

Michael Morris, MD

morrism@mskcc.org

646-422-4471

Lisa Bodei, MD, PhD

bodeil@mskcc.org

212-639-7373

Government Study Link:

NCT06941480 - Click here to see study on

ClinicalTrials.gov

Drug Details

177Lu-DTPA-SC16.56
Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • DLL3
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468